Upadacitinib Mechanism and Clinical Applications

Introduction to Upadacitinib

Upadacitinib blocks signaling of multiple inflammatory cytokines that rely on the JAK-STAT pathway, which is a key mechanism in its therapeutic effects 1
It specifically reduces immunopathogenic gene expression induced by type 1 interferons (IFNα/IFNβ), contributing to its anti-inflammatory properties 2

The American College of Rheumatology recommends upadacitinib as a standard of care for refractory rheumatoid arthritis, due to its selective JAK1 inhibition 2
Upadacitinib is approved for moderate-to-severe atopic dermatitis, demonstrating efficacy in reducing disease severity 3
It has shown efficacy in inflammatory bowel disease, including ulcerative colitis and Crohn's disease, and ankylosing spondylitis, making it a valuable treatment option for these conditions 1
The drug is effective for signs and symptoms in patients with active psoriatic arthritis, providing an additional treatment option for this condition 1

Upadacitinib's selectivity for JAK1 may contribute to its efficacy profile in certain conditions, while potentially affecting its safety profile 1
Higher doses of upadacitinib (30 mg daily) demonstrate higher efficacy at reducing disease severity scores compared to other JAK inhibitors like baricitinib 3
Upadacitinib carries FDA warnings about increased risk of serious infections, cardiovascular events, malignancy, and thrombosis, highlighting the need for careful patient monitoring 1, 3
Appropriate laboratory monitoring is recommended before and during treatment with upadacitinib to minimize potential risks 3